Clene stock maintains Buy rating at Benchmark on positive MS data
PositiveFinancial Markets

Clene's stock has received a 'Buy' rating from Benchmark following encouraging data related to multiple sclerosis (MS). This positive assessment highlights the company's potential in the healthcare market, especially as it continues to develop treatments for MS. Investors are optimistic about Clene's future, as the positive data could lead to increased interest and investment in their products.
— Curated by the World Pulse Now AI Editorial System